Human CD98 Protein, His Tag (MALS verified)
分子別名(Synonym)
SLC3A2,CD98,4F2,4F2HC,4T2HC,CD98HC,MDU1,NACAE
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CD98, His Tag (CD8-H5247) is expressed from human 293 cells (HEK293). It contains AA Arg 206 - Ala 630 (Accession # AAH01061).
Predicted N-terminus: His
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 47.7 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
CD抗原CD98又稱4F2細(xì)胞表面抗原重鏈(4F2hc)、4F2重鏈抗原、溶質(zhì)載體家族3成員2(SLC3A2)、淋巴細(xì)胞活化抗原4F2大亞基,是一種單程I型膜蛋白,屬于SLC3A轉(zhuǎn)運(yùn)蛋白家族。SLC3A2/CD98在所有受試組織中普遍表達(dá),在腎臟、胎盤和睪丸中檢測(cè)到最高水平,在胸腺中檢測(cè)到最低水平。SLC3A2/CD98是輕鏈氨基酸轉(zhuǎn)運(yùn)蛋白功能所必需的,也參與苯丙氨酸、酪氨酸、亮氨酸、精氨酸和色氨酸等大中性氨基酸的非鈉依賴性、高親和力轉(zhuǎn)運(yùn)。CD98參與引導(dǎo)和靶向LAT1和LAT2至質(zhì)膜。當(dāng)與SLC7A5或SLC7A8結(jié)合時(shí),CD98通過跨膜立體選擇性運(yùn)輸L-亞硝基半胱氨酸(L-CNSO)參與小分子量亞硝基硫醇的細(xì)胞活性。與ICAM1一起,通過產(chǎn)生和傳遞細(xì)胞內(nèi)信號(hào)來(lái)調(diào)節(jié)極化腸細(xì)胞中的LAT2轉(zhuǎn)運(yùn)活性。
關(guān)鍵字: CD98;CD98蛋白;CD98重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。